Treating Anemia in Older Adults with Heart Failure with a Preserved Ejection Fraction (HFPEF) with Epoetin Alfa: Single Blind Randomized Clinical Trial of Safety and Efficacy

摘要

BackgroundAnemia is a common co-morbidity in older adults with heart failure and a preserved ejection fraction (HFPEF) and is associated with worse outcomes. We hypothesized that treating anemia with subcutaneous epoetin alfa (ESA) would be associated with reverse ventricular remodeling and improved exercise capacity and health status compared with placebo.